Can-Fite Biopharma Overview
Valuation check: CANF's ROE is -175.75%, below the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow-175.75%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for CANF is -175.75%. That is below the Healthcare sector average of 20.86%. Investors often review this figure alongside Can-Fite Biopharma's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, CANF currently prints -175.75% for ROE, while the sector average sits near 20.86%. That is roughly 942.7% below the sector mean. Large gaps often invite a closer look at Can-Fite Biopharma's growth, margins, and balance sheet.
Return on Equity shows how effectively Can-Fite Biopharma converts resources into returns. At -175.75%, CANF may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting CANF's ROE (-175.75%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Can-Fite Biopharma's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
